Technology

Technology
Nexavant

NEXAVANT®, the novel TLR3 agonist*

  • 1 A defined TLR3 agonist homogeneity
  • 2 RNAse A and heat resistant
  • 3Stable for more than two years at 42oC
  • 4 TLR3 and RIGI agonist without MDA5 activation
  • 5 Available for Scale-up production in GMP grade
  • 6 CAS registered
  • 7 More than 99% purity in HPLC
  • 8 Capable for more than 10 million dose production/year
  • 9 Strong immune stimulant: https://pubmed.ncbi.nlm.nih.gov/36761735/
  • 10 Potent anticancer effect: https://pubmed.ncbi.nlm.nih.gov/38136298/
  • 11 Mixed Th1/Th2, induced CD4 and CD8
  • 12 DS for the following development:
  • Vaccine adjuvant
  • Anti PD-1 dual therapy
  • Adjuvant for a cross-reactive flu vaccine
  • Drug substance for regeneration therapy
  • Peptide complex drug development

NexaVant®, a homologous, stable, and high purity product

  • Homogeneity

  • Stability I

  • Purity

  • Stability II